Genentech Inc. could seek regulatory approval early next year for an experimental drug that in a late-stage trial showed that it could slow progression of a tough-to-treat form of multiple sclerosis, at least in the short term.
The drug, a humanized monoclonal antibody called ocrelizumab, would be a huge win for the South San Francisco-based biotech powerhouse, as well as its parent company Roche (SWX: RO), and MS patients.
Deutsche Bank (NYSE: DB)'s Tim Race told Reuters that the drug could generate $5 billion in annual sales.
Help employers find you! Check out all the jobs and post your resume.
